We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+16.08%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$232M
AUM Growth
-$281M
(-55%)
Cap. Flow
-$304M
Cap. Flow
% of AUM
-130.94%
Top 10 Holdings %
Top 10 Hldgs %
35.11%
Holding
133
New
10
Increased
39
Reduced
47
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$4.1M |
| 2 |
SLRN
ACELYRIN
SLRN
|
+$2.78M |
| 3 |
Merck
MRK
|
+$2.54M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$2.3M |
| 5 |
Travere Therapeutics
TVTX
|
+$2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$11.2M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$10.6M |
| 3 |
HealthEquity
HQY
|
+$10.5M |
| 4 |
Evolent Health
EVH
|
+$10.4M |
| 5 |
RadNet
RDNT
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
76
DELISTED
Immunogen Inc
IMGN
| $531K | 0.23% |
17,896
-446,216
| -96% | -$8.89M |
|
77
BridgeBio Pharma
BBIO
$15.7B
| $523K | 0.23% |
12,955
-167,240
| -93% | -$5.02M |
|
78
Vaxcyte
PCVX
$7.81B
| $506K | 0.22% |
8,050
-113,180
| -93% | -$5.88M |
|
79
Jazz Pharmaceuticals
JAZZ
$15.9B
| $504K | 0.22% |
4,094
+180
| +5% | +$22.5K |
|
80
Acadia Pharmaceuticals
ACAD
$4.43B
| $472K | 0.2% |
15,060
-194,900
| -93% | -$4.65M |
|
81
Insmed
INSM
$21.4B
| $428K | 0.18% |
13,811
-333,581
| -96% | -$8.65M |
|
82
Alkermes
ALKS
$8.22B
| $425K | 0.18% |
15,330
-228,930
| -94% | -$5.95M |
|
83
Medpace
MEDP
$16.1B
| $420K | 0.18% |
1,371
+190
| +16% | +$51.3K |
|
84
Roivant Sciences
ROIV
$24.5B
| $409K | 0.18% |
36,457
+6,010
| +20% | +$58.6K |
|
85
Revolution Medicines
RVMD
$39.9B
| $393K | 0.17% |
13,710
-128,940
| -90% | -$3.1M |
|
86
BioNTech
BNTX
$22.9B
| $393K | 0.17% |
3,725
+280
| +8% | +$28.2K |
|
|
MRTX
87
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $380K | 0.16% |
6,474
-175,430
| -96% | -$9.86M |
|
88
Rocket Pharmaceuticals
RCKT
$340M
| $368K | 0.16% |
12,280
-214,750
| -95% | -$4.74M |
|
89
Exelixis
EXEL
$13.3B
| $336K | 0.14% |
13,990
+1,510
| +12% | +$32.8K |
|
90
Ionis Pharmaceuticals
IONS
$8.6B
| $328K | 0.14% |
+6,480
| New | +$310K |
|
91
Dr. Reddy's Laboratories
RDY
$9.87B
| $313K | 0.13% |
22,500
| – | – |
|
|
APLS
92
DELISTED
Apellis Pharmaceuticals
APLS
| $312K | 0.13% |
5,220
| – | – |
|
93
Intellia Therapeutics
NTLA
$1.49B
| $284K | 0.12% |
9,300
-103,032
| -92% | -$2.96M |
|
94
Madrigal Pharmaceuticals
MDGL
$10.8B
| $278K | 0.12% |
1,201
-19,700
| -94% | -$3.45M |
|
95
Denali Therapeutics
DNLI
$3.65B
| $276K | 0.12% |
12,881
-242,060
| -95% | -$4.79M |
|
96
Olema Pharmaceuticals
OLMA
$1B
| $270K | 0.12% |
19,230
-418,422
| -96% | -$5.62M |
|
97
Arrowhead Research
ARWR
$11.9B
| $250K | 0.11% |
8,182
-149,370
| -95% | -$3.97M |
|
|
BPMC
98
DELISTED
Blueprint Medicines
BPMC
| $228K | 0.1% |
2,470
-163,420
| -99% | -$10.6M |
|
99
Halozyme
HALO
$9.79B
| $223K | 0.1% |
6,030
-139,970
| -96% | -$5.27M |
|
100
Legend Biotech
LEGN
$3.59B
| $181K | 0.08% |
3,000
-3,670
| -55% | -$233K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Sectoral Asset Management held 133 positions worth $232M, down 55% from $514M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Sectoral Asset Management withdrew a net $304M in Q4 2023, closing 29 positions and reducing 47 holdings. Its most notable exit was R1 RCM Inc. Common Stock, an estimated $11.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in ACELYRIN worth $2.43M.
- Sectoral Asset Management's largest Q4 2023 buy was ACELYRIN: 325,549 shares worth $2.43M.
- Sectoral Asset Management added most to argenx in Q4 2023, an estimated $4.1M increase.
- Sectoral Asset Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $10.6M.
- Sectoral Asset Management fully exited R1 RCM Inc. Common Stock in Q4 2023, selling an estimated $11.2M.
- Sectoral Asset Management's ten largest holdings make up 35% of its $232M portfolio in Q4 2023.
- Sectoral Asset Management opened 10 new positions and closed 29 in Q4 2023.
- Sectoral Asset Management's portfolio value fell 55% quarter-over-quarter to $232M.
Based on Sectoral Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.